Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients  by Matsumoto, Tetsuya et al.
Systemic and Pulmonary Hypertension
Angiotensin-Converting Enzyme Inhibition
But Not Angiotensin II Type 1 Receptor
Antagonism Augments Coronary Release of
Tissue Plasminogen Activator in Hypertensive Patients
Tetsuya Matsumoto, MD, Kazuo Minai, MD, Hajime Horie, MD, Naoto Ohira, MD,
Hiroyuki Takashima, MD, Yasuhiro Tarutani, MD, Yo Yasuda, MD, Tomoya Ozawa, MD,
Shinro Matsuo, MD, Masahiko Kinoshita, MD, Minoru Horie, MD
Shiga, Japan
OBJECTIVES We compared the effects of perindopril and losartan on endothelium-dependent coronary
vasomotor and fibrinolytic function.
BACKGROUND The renin-angiotensin system regulates the vascular fibrinolytic balance. However, the effects
of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists on
coronary fibrinolytic function have not been compared in hypertensive patients.
METHODS Forty-five patients with hypertension were randomly assigned to three groups: 16 patients
were treated with perindopril (4 mg/day) for four weeks; 15 were treated with losartan (50
mg/day) for four weeks; and 14 were not treated with either perindopril or losartan (control
group). Graded doses of bradykinin (BK) (0.2, 0.6, and 2.0 g/min) were administered into
the left coronary artery. Coronary blood flow (CBF) was evaluated by Doppler flow velocity
measurement.
RESULTS Bradykinin induced dose-dependent increases in CBF in all groups. The increases in CBF
induced by BK in the perindopril and losartan groups were significantly greater than those in
the control group. Net coronary tissue-type plasminogen activator (t-PA) release was
enhanced by BK in all groups, and the increase in the perindopril group was greater than that
in the losartan and control groups. Bradykinin did not alter plasminogen activator inhibitor
type 1 levels in any of the groups.
CONCLUSIONS Perindopril and losartan similarly augment BK-induced coronary vasodilation. Perindopril
may have a greater potential to enhance the BK-induced coronary release of t-PA than
losartan. (J Am Coll Cardiol 2003;41:1373–9) © 2003 by the American College of
Cardiology Foundation
Impairment of fibrinolysis is an established risk factor for
thrombotic events such as stroke and myocardial infarction
(1,2). Thus, it is important to evaluate the role of fibrinolysis
in the pathophysiology of cardiovascular disease. Fibrino-
lytic activity is primarily determined by the balance between
the levels of tissue-type plasminogen activator (t-PA) and
plasminogen activator inhibitor type 1 (PAI-1) (3,4).
The fibrinolytic system and the renin-angiotensin system
are linked through angiotensin-converting enzyme (ACE)
(5–7). The ACE inhibitors are thought to favorably alter
the fibrinolytic balance by increasing bradykinin (BK)-
induced t-PA release, by decreasing angiotensin II–
mediated PAI-1 release, or by both (6,7). We recently
demonstrated that ACE inhibitors augment BK-induced
t-PA release in human coronary circulation (8).
There is a growing body of evidence that ACE inhibitors
and angiotensin II type 1 (AT1) receptor antagonists improve
peripheral and coronary vascular endothelial dysfunction
(9–11). Based on the results of animal experiments, they can
improve endothelial dysfunction by reducing angiotensin II–
induced NADH-oxidase–mediated superoxide formation (12).
In addition, unlike AT1 receptor antagonists, ACE inhibitors
inhibit BK breakdown, thus enhancing plasma levels of BK
and the subsequent release of nitric oxide (NO), prostacyclin,
and endothelium-derived hyperpolarizing factor from the vas-
cular endothelium. Previous comparative studies have shown
that ACE inhibitors and AT1 receptor antagonists differ in
their effects on fibrinolysis in the peripheral circulation (13–
16). However, the effects of AT1 receptor antagonists on
endothelium-dependent vasomotion and fibrinolysis in the
human coronary circulation, as compared with the effects of
ACE inhibitors, have not yet been assessed.
The aim of the present study was to compare the effects
of an ACE inhibitor, perindopril, and an AT1 receptor
antagonist, losartan, on BK-induced fibrinolytic and vaso-
motor responses in the human coronary circulation.
METHODS
Study patients. The study population consisted of 45
patients with atypical chest pain and hypertension (systolic
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blood pressure 140 mm Hg or diastolic blood pressure
90 mm Hg at the time of recruitment into the study) who
underwent diagnostic cardiac catheterization and were
shown to have angiographically normal coronary arteries.
Secondary hypertension was excluded on the basis of a
history, physical examination, and appropriate laboratory
tests (including a renal arteriogram, if indicated). Patients
with diabetes mellitus, myocardial infarction, congestive
heart failure (HF), cardiomyopathy, or valvular heart disease
were also excluded. Forty-five patients were randomly as-
signed to three groups: 16 patients were treated with the
ACE inhibitor perindopril (4 mg/day) for four weeks; 15
were treated with the AT1 antagonist losartan (50 mg/day)
for four weeks; and 14 were not treated with ACE inhibi-
tors or AT1 antagonists (control group). All cardiac medi-
cations except for ACE inhibitors and AT1 antagonists
were discontinued for at least 72 h before the study. For at
least seven days before the study, the subjects received a
low-sodium diet (NaCl 5 g/day). The Ethical Committee
on Human Research of our institution approved the study
protocols, and written, informed consent was obtained from
all patients.
Protocol. All patients received the last dose of perindopril
or losartan at 7 AM, and cardiac catheterization was per-
formed between 9 and 11 AM in the fasting state. A
0.014-in. Doppler-tipped guide wire (FloWire, Cardiomet-
rics Inc., Mountain View, California) was advanced to the
area between the proximal and middle segments of the left
anterior descending coronary artery to measure blood flow
velocity, as previously described (8). All drugs were infused
directly into the left main coronary artery via the guide
catheter at infusion rates ranging from 0.5 to 1 ml/min. A
6F multipurpose catheter (GCS6, Goodtec, Gifu, Japan)
was inserted via the right femoral vein into the coronary
sinus (CS) for blood sampling. Baseline coronary blood flow
(CBF) velocity measurement, blood sampling, and coronary
angiography were performed. The following studies were
then performed. 1) Bradykinin was started at 0.2 g/min
and then increased to 0.6 and 2.0 g/min for 2 min. During
BK infusion, CBF velocity reached a peak at about 60 s and
maintained a plateau by 60 s. 2) After completing the
protocol with the intracoronary injection of BK, we waited
for at least 10 min before beginning the infusion of
papaverine, by which time the coronary diameter and CBF
velocity had returned to their baseline values. 3) Finally,
papaverine (an endothelium-independent vasodilator) was
administered into the left coronary artery at 12 mg over 20 s.
Coronary angiography was performed after each infusion.
Quantitative coronary angiography and measurement of
CBF. Coronary cineangiograms were recorded using a
Philips cineangiographic system (Philips Medical Systems,
Tokyo, Japan). The change in the diameter of the left
anterior descending coronary artery was measured in a vessel
segment 5 mm beyond the tip of the Doppler wire.
Coronary angiography was performed using the Judkins
technique with contrast material (Omnipaque, Dai-ichi
Pharmaceutical Co., Tokyo, Japan). Coronary angiograms
were analyzed by quantitative coronary angiography, using
the Cardiovascular Measurement System (CMS-MEDIS
Medical Imaging Systems, Leiden, The Netherlands). Peak
CBF velocity was continuously monitored using a fast
Fourier transform–based spectral analyzer (FloMap, Car-
diometrics Inc.). Coronary blood flow was derived from the
CBF velocity, and measurements of the diameter were
derived by the formula:   average peak CBF velocity 
0.125  (arterial diameter)2 (17). Coronary vascular resis-
tance (CVR) was calculated as the mean arterial pressure
(MAP) divided by CBF.
Phasic pressure and MAP, heart rate, and 12-lead elec-
trocardiograms were continuously monitored using a poly-
graph system (Nihon-Kohden Kogyo Co., Tokyo, Japan)
and recorded on a multichannel recorder.
Blood sampling and biochemical assays. Paired blood
samples in the aorta (Ao) and CS were taken simultaneously
before infusion of BK and after infusion of BK and
papaverine for the measurement of t-PA antigen and
antibody and PAI-1 antigen, as previously described (8).
Blood samples were collected on ice and centrifuged
immediately, and plasma was stored at70°C until the time
of assay. Blood for the measurement of t-PA and PAI-1 was
collected in tubes containing citrate and acidified buffered
citrate. Antigen levels were determined using two-site
ELISA (Biopool, AB, Umea, Sweden) (8). In samples
obtained from seven patients in the control group, eight
patients in the perindopril group, and eight patients in the
losartan group in a randomized manner, plasma levels of
t-PA activity were determined by a photometric method
(Chromolize t-PA, Biopool, AB). Blood for the measure-
ment of plasma levels of the plasma-active renin concentra-
tion, aldosterone, epinephrine, norepinephrine, angiotensin
I, and angiotensin II was collected in tubes containing
EDTA (1 mg/ml). The plasma-active renin concentration
and aldosterone levels were measured using commercial
radioimmunoassay kits. Plasma epinephrine and norepi-
nephrine concentrations were measured by high-
performance liquid chromatography. Plasma angiotensin I
and angiotensin II levels were measured by radioimmuno-
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
Ao  aorta
AT1  angiotensin II type 1
BK  bradykinin
CBF  coronary blood flow
CS  coronary sinus
CVR  coronary vascular resistance
HF  heart failure
MAP  mean arterial pressure
NO  nitric oxide
t-PA  tissue-type plasminogen activator
PAI-1  plasminogen activator inhibitor type 1
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assay, using a specific antibody (Special Research Labora-
tory, Tokyo, Japan).
Arteriovenous concentration gradients were calculated by
subtracting the plasma level measured in simultaneously
collected arterial and CS venous blood. Thus, the net release
or uptake rates at each time point were calculated as: net
release  (concentrationCS  concentrationAo)  (CBF 
[(100  hematocrit)/100]) .
Statistics. Data are expressed as the mean value  SEM.
Discrete variables were expressed as counts or percentages
and compared using the chi-squared test. Continuous vari-
ables were compared using the unpaired Student t test or
one-way analysis of variance (ANOVA). When serial
changes in systemic and coronary hemodynamic variables
and fibrinolytic parameters in response to graded doses of
BK were compared, we used two-way ANOVA for repeated
measures, followed by the Bonferroni multiple comparisons
test, between groups; and we used one-way ANOVA within
each group (StatView version 5.0). A value of p  0.05 was
considered statistically significant.
RESULTS
Baseline characteristics and neurohormonal factors.
There were no significant differences in baseline character-
istics among the control, perindopril, and losartan groups
(Table 1).
There were no significant differences in aldosterone,
epinephrine, or norepinephrine among the control, perin-
dopril, and losartan groups after one month of treatment.
Plasma-active renin concentration levels in the perindopril
and losartan groups were higher than those in the control
group. The level of ACE in the perindopril group was lower
than that in the control and losartan groups. Levels of
angiotensin I and II in the losartan group were higher than
those in the control and perindopril groups (Table 2).
Systemic and coronary hemodynamics. As shown in Fig-
ure 1, intracoronary infusion of BK resulted in a significant
decrease in MAP in the perindopril group, and this effect
was dose-dependent. However, BK did not alter MAP in
the control or losartan group. After infusion of each of three
graded doses of BK, MAP was significantly lower in the
perindopril and losartan groups than in the control group.
With increasing doses of BK, the heart rate did not change
in either group (Fig. 1). The addition of 12 mg papaverine
did not affect MAP or heart rate in either group. Intracoro-
nary infusion of BK increased CBF and decreased CVR in
a dose-dependent manner in all three groups (Fig. 2). The
increases in CBF and decreases in CVR induced by the
three doses of BK in both the perindopril and losartan
groups were significantly greater than those in the control
group. No significant differences were observed in the CBF
and CVR responses to BK between the perindopril and
losartan groups. Intracoronary infusion of papaverine caused
similar increases in CBF and decreases in CVR in the three
groups (Fig. 2).
Fibrinolytic parameters. The basal levels of t-PA antigen
at either the Ao or CS did not differ among the three groups
(control group: Ao 6.3  0.8 ng/ml, CS 6.3  0.7 ng/ml;
perindopril group: Ao 6.3  0.7 ng/ml, CS 6.9  0.9
ng/ml; losartan group: Ao 5.1  0.8 ng/ml, CS 5.2  0.9
ng/ml). The level of t-PA in the Ao was not changed by the
infusion of BK in any of the three groups (Fig. 3, left). The
levels of t-PA in the CS in all three groups were signifi-
cantly increased in a dose-dependent manner by the infu-
sion of graded doses of BK (Fig. 3, right). The level of t-PA
Table 1. Baseline Characteristics
Control
Group
Perindopril
Group
Losartan
Group
Age (yrs) 59.3  2.8 64.7  2.9 66.0  4.3
Gender (male/female) 9/5 9/7 10/5
Smokers 5 (36%) 6 (38%) 5 (33%)
Body mass index (kg/m2) 23.5  0.7 22.5  0.7 23.3  1.2
Mean arterial pressure (mm Hg) 110.8  3.9 98.1  3.3* 96.6  5.5*
Heart rate (beats/min) 63.4  2.8 66.0  3.6 65.6  4.3
Baseline CBF (ml/min) 23.4  2.6 18.4  1.8 21.8  3.4
Baseline CVR (mm Hg/ml per min) 4.74  0.74 5.33  0.62 4.45  0.77
Total cholesterol (mg/dl) 187.5  6.0 192.6  6.4 190.7  15.4
HDL cholesterol (mg/dl) 46.8  2.8 48.0  7.1 39.2  3.1
Triglycerides (mg/dl) 124.7  9.0 127.2  13.1 141.5  14.7
Hematocrit (%) 40.7  0.6 39.4  1.0 39.7  1.5
*p  0.05 versus control group. Data are presented as the mean value  SEM or number (%) of subjects.
CBF  coronary blood flow; CVR  coronary vascular resistance; HDL  high-density lipoprotein.
Table 2. Neurohormonal Values
Control
Group
Perindopril
Group
Losartan
Group
PARC (pg/ml) 12.3  3.0 53.0  28.0* 75.7  29.8*
Aldosterone (pg/ml) 77.2  7.4 73.7  11.9 66.8  9.1
ACE (IU/l) 9.9  0.8 3.6  1.2* 8.8  0.9†
Epinephrine (pg/ml) 82.3  16.2 71.5  12.9 65.0  33.7
Norepinephine (pg/ml) 240  28 242  48 294  46
Angiotensin I (pg/ml) 149  38 280  110 460  183*
Angiotensin II (pg/ml) 7.83  1.64 8.57  2.20 32.5  10.6*†
*p  0.05 versus control group. †p  0.05 versus perindopril group. Data are
presented as the mean value  SEM.
ACE  angiotensin-converting enzyme; PARC  plasma-active renin concen-
tration.
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in response to BK in the CS in the perindopril group was
significantly higher than that in the control and losartan
groups. The net t-PA release induced by the intracoronary
infusion of BK was increased in all three groups, and the
increase in the perindopril group was markedly greater than
that in the control and losartan groups (Fig. 4). Baseline
levels of plasma t-PA activity in the Ao and CS were 0.5
IU/ml in the three groups (control group: n 7; perindopril
group: n 8; losartan group: n 8). Bradykinin at doses of
0.2, 0.6, and 2.0 g/min did not significantly increase
plasma levels of t-PA activity in the control and losartan
groups. Increases in t-PA activity across the coronary
circulation were observed only after infusion of BK at doses
of 0.6 and 2.0 g/min in the perindopril group (0.6 g/min
BK: Ao 0.5 IU/ml, CS 2.2  0.8 IU/ml; 2.0 g/min BK:
Ao 0.5 IU/ml, CS 4.9  1.6 IU/ml). Intracoronary
infusion of papaverine did not alter the level of t-PA in
either the Ao or CS in any of the three groups.
The basal levels of PAI-1 in both the Ao and CS in the
control group tended to be higher than respective levels in
the other two groups, but these differences were not signif-
icant (control group: Ao 6.2  0.8 ng/ml, CS 6.8  1.2
ng/ml; perindopril group: Ao 5.1  0.8 ng/ml, CS 5.5 
1.0 ng/ml; losartan group: Ao 4.7  0.9 ng/ml, CS 5.1 
1.2 ng/ml) (Fig. 5). With an increase in the dosage of BK,
the level of PAI-1 in the CS tended to decrease, compared
with that in the Ao, in all three groups. However, there were
no significant differences among the three groups. Papaver-
ine also had no significant effects on the level of PAI-1 in
either the Ao or CS in any group (Fig. 5).
DISCUSSION
Principal findings. The major findings of the present study
are as follows: AT1 receptor antagonism and ACE inhibi-
tion augmented endothelium-mediated vasodilation in-
duced by BK in human coronary circulation. Also, ACE
inhibition potentiated the ability of BK to stimulate the
release of t-PA in the human coronary circulation, which is
not observed with AT1 receptor antagonism.
Endothelial vasomotor function. Four weeks of therapy
with the ACE inhibitor perindopril or the AT1 receptor
antagonist losartan augmented the BK-induced CBF and
CVR responses to a similar extent. Although many clinical
studies have found that ACE inhibitors improve endothelial
function under various conditions (9,10,18), it is not clear
whether AT1 receptor antagonists have beneficial effects
comparable to those of ACE inhibitors. Treatment with
perindopril for three months improved the forearm blood
flow response induced by acetylcholine in patients with
congestive HF who improved clinically (9). The Trial on
Reversing ENdothelial Dysfunction (TREND) study
Figure 1. The effects of bradykinin (0.2, 0.6, and 2.0 g/min) and
papaverine (PA) (12 mg) on mean arterial pressure (upper panel) and heart
rate (lower panel) in the control group (solid circles), perindopril group
(solid triangles), and losartan group (open squares). *p  0.05 versus
baseline.
Figure 2. The effects of bradykinin (0.2, 0.6, and 2.0 g/min) and
papaverine (PA) (12 mg) on percent changes in coronary blood flow and
vascular resistance in the control group (solid circles), perindopril group
(solid triangles), and losartan group (open squares).
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showed that quinapril improved acetylcholine-induced cor-
onary vasomotor function in normotensive patients with
coronary artery disease (10). Recently, Prasad et al. (11,19)
showed that losartan improved flow-mediated brachial and
coronary artery dilation in patients with atherosclerosis.
The ACE inhibitors may act on kininase II and increase
tissue concentrations of BK, which would augment vasodi-
lation through the release of NO, prostacyclin, and
endothelium-derived hyperpolarizing factor. In addition,
angiotensin II strongly stimulates NADH/NADPH-
oxidase-dependent vascular superoxide anion generation
(20,21). Thus, ACE inhibitors and AT1 receptor antago-
nists may enhance BK-induced coronary vasodilation partly
through increased NO bioavailability by reducing vascular
angiotensin II production (22).
Tissue-type plasminogen activator. This is a serine pro-
tease released from endothelial cells through translocation
of a dynamic intracellular storage pool. The effectiveness of
plasminogen activation and fibrin degradation is regulated
by the relative balance between the local release of t-PA and
its subsequent inhibition via the formation of complexes
with PAI-1.
In the present study, baseline t-PA antigens in both the
Ao and CS were similar among the three groups. There
have been only a few direct comparison studies on the effects
of ACE inhibitors and AT1 receptor antagonists on fibri-
nolysis. In one study, the administration of losartan, but not
quinapril, for three weeks reduced the plasma t-PA antigen
concentration in normotensive subjects under activation of
the renin-angiotensin-aldosterone system (13). Similarly,
immediate administration of losartan, but not enalapril,
reduced the plasma t-PA antigen concentration in patients
with HF (14). Other comparative studies showed that
plasma t-PA antigen concentrations were unchanged in
patients with hypertension using two therapeutic regimens
(15).
In the present study, the CBF and CVR responses and
net t-PA release induced by BK were significantly increased
in the perindopril group compared with the control group.
AT1 receptor antagonism did not influence the effect of BK
on t-PA release, despite the augmented BK-induced CBF
response. On the contrary, Labinjoh et al. (23) reported that
seven days of treatment with losartan (50 mg/day) did not
change the blood flow response and t-PA release induced by
BK in the forearm circulation. In the present study, plasma
concentrations of angiotensin II in the losartan group were
higher than those in the perindopril and control groups.
There have been some reports that blockade of AT1
receptors may cause the generation of NO mediated by BK
from the endothelium through an increase in plasma angio-
tensin II and stimulation of AT2 receptors (24,25). Our data
suggest that AT2 receptor stimulation may have little, if any,
effect on coronary net t-PA release in response to BK.
Tranquille and Emeis (26) reported that blockade of NO
did not affect BK-stimulated t-PA release. Brown et al. (27)
reported that BK stimulates t-PA release from the forearm
vascular endothelium through a B2 receptor–dependent,
NO synthase–independent, and cyclooxygenase-
independent pathway. They suggested that endothelium-
derived hyperpolarizing factor may contribute to BK-
stimulated t-PA release. Interestingly, Node et al. (28)
suggested that epoxyeicosatrienoic acids, which share many
of the properties of endothelium-derived hyperpolarizing
factor (29), possess fibrinolytic properties through the in-
Figure 3. The effects of bradykinin (0.2, 0.6, and 2.0 g/min) and papaverine (PA) (12 mg) on tissue-type plasminogen activator (t-PA) antigen in the
aorta (Ao) and coronary sinus (CS) in the control group (solid circles), perindopril group (solid triangles), and losartan group (open squares). *p  0.05
versus baseline.
Figure 4. The effects of bradykinin (0.2, 0.6, and 2.0 g/min) and
papaverine (PA) (12 mg) on net tissue-type plasminogen activator (t-PA)
release in the control group (solid circles), perindopril group (solid
triangles), and losartan group (open squares). *p  0.05 versus baseline.
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duction of t-PA expression without affecting PAI-1 in
vascular endothelial cells. Further studies are needed to
examine whether endothelium-derived hyperpolarizing fac-
tor could contribute to coronary t-PA release in response to
BK and, if so, to determine the mechanism.
As far as the human coronary circulation is concerned,
ACE inhibition may have greater beneficial effects than
AT1 receptor antagonism by increasing BK-induced t-PA
release, even if ACE inhibition and AT1 receptor antago-
nism may have similar beneficial effects on BK-induced
coronary vasodilation. The present results may be associated
with the beneficial effects of ACE inhibitors on the ob-
served incidence of coronary thrombotic events in several
previous randomized clinical trials.
Plasminogen activator inhibitor-1. Our study demon-
strates that the basal levels of PAI-1 in both the Ao and CS
did not significantly differ among the three groups. Good-
field et al. (14) recently reported that ACE inhibition with
enalapril and AT1 receptor antagonism with losartan low-
ered PAI-1 antigen in chronic HF patients. Another recent
report showed that levels of PAI-1 antigen were reduced
after treatment with either an ACE inhibitor (perindopril)
or AT1 receptor antagonist (losartan) among patients with
hypertension (15). In contrast, trandolapril decreased PAI-1
levels, whereas losartan did not, in hypertensive postmeno-
pausal women (16). Similar results were found in a com-
parison of quinapril and losartan in normotensive subjects
under activation of the renin-angiotensin system (13).
In the present study, PAI-1 levels at the CS, but not the
Ao, tended to decrease with increasing doses of BK in all
three groups. Nagata et al. (30) showed that ACE inhibi-
tion, but not AT1 receptor antagonism, decreased PAI-1
synthesis in human cultured monocytes, suggesting that BK
may be involved in PAI-1 synthesis. Many factors influence
the production of PAI-1 (e.g., glucose, insulin, estrogen,
angiotensin II). Further studies are needed to determine
whether t-PA release induced by BK is associated with
PAI-1 synthesis and clearance in human coronary circula-
tion.
Conclusions. AT1 receptor antagonism and ACE inhibi-
tion augment endothelium-mediated vasodilation induced
by BK in human coronary circulation. Angiotensin-
converting enzyme inhibition potentiates the ability of BK
to stimulate the release of t-PA in the human coronary
circulation, which is not seen with AT1 receptor antago-
nism. The present study raised the possibility that ACE
inhibitors may have a greater potential to induce coronary
fibrinolytic activity, and thus reduce the prevalence of
thrombotic cardiovascular events, than AT1 receptor antag-
onists.
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